Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutation in ER-negative and HER2-positive breast cancer with apocrine differentiation.

Breast cancer (Tokyo, Japan) - 1 May 2026

Nozaki Fumi, Nakanishi Yoko, Hirotani Yukari, Kobayashi Hiroko, Tanino Tomoyuki, Nishimaki-Watanabe Haruna, Ohni Sumie, Tang Xiaoyan, Masuda Shinobu

Abstract excerpt

BACKGROUND: Targeted therapies for PIK3CA-mutated breast cancer are currently limited to the hormone receptor (HR)-positive and HER2-negative subtype. Carcinoma with apocrine differentiation (apocrine ca.) is typically characterized as ER-negative and HER2-positive/negative. Consequently, patients with apocrine ca. are generally excluded from PIK3CA genotyping and targeted therapies, even when mutations are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Differentiation

Share to Cell Line, Tumor

Share to Cell Proliferation

Share to Class I Phosphatidylinositol 3-Kinases

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Receptors, Estrogen

Source

Identifiers

PMID: 41729430
DOI: 10.1007/s12282-026-01837-4

Genes

PIK3CA
AR
MB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutation in ER-negative and HER2-positive breast cancer with apocrine differentiation.PMID 41729430Read ↗

Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.Semantic proximity Read ↗

Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.Semantic proximity Read ↗

HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and OutcomeSemantic proximity Read ↗

Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.Semantic proximity Read ↗

Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high-frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis.Semantic proximity Read ↗

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.Semantic proximity Read ↗

Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studiesSemantic proximity Read ↗

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Semantic proximity Read ↗

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeSemantic proximity Read ↗

Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.Semantic proximity Read ↗

Neoadjuvant Chemotherapy Response in Triple-Negative Apocrine Carcinoma: Comparing Apocrine Morphology, Androgen Receptor, and Immune Phenotypes.Semantic proximity Read ↗

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.